AffiliationDepartment of Medical Oncology, Gustave Roussy, Villejuif, France
MetadataShow full item record
AbstractAs originator biologic medicines lose patent protection, some biopharmaceutical companies are focusing on developing similar versions of these costly and complex therapies with a goal of providing more affordable treatment options. Many of these molecules, known as biosimilars, are now approved worldwide and several more are expected to be introduced in the near future. As more biosimilars become available, it is important for clinicians to become familiar with this new category of products and understand how biosimilars are developed, how their development differs from that of originator biologics and how they differ from generics. This review aims to provide the practicing clinician with the knowledge needed to understand biosimilars, along with some guidance on their use in treating oncologic diseases.
CitationThill M, Thatcher N, Hanes V, Lyman G. Biosimilars: what the oncologist should know. Future Oncol. 2019.
- Biosimilar safety considerations in clinical practice.
- Authors: Choy E, Jacobs IA
- Issue date: 2014 Feb
- Biosimilars in Oncology in the United States: A Review.
- Authors: Nabhan C, Parsad S, Mato AR, Feinberg BA
- Issue date: 2018 Feb 1
- The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
- Authors: Declerck P, Danesi R, Petersel D, Jacobs I
- Issue date: 2017 Apr
- Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.
- Authors: Scheinberg M, Pineda C, Castañeda-Hernández G, Zarbá JJ, Damião A, Arantes LH Jr, Jacobs I
- Issue date: 2018 Aug/Sep
- [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
- Authors: Schreiber S, Luger T, Mittendorf T, Mrowietz U, Müller-Ladner U, Schröder J, Stallmach A, Bokemeyer B
- Issue date: 2014 Nov